Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Knopp Neurosciences completes series B2 financing
Proceeds from the offering will be used to advance Knopp’s discovery research targeting mitochondrial mechanisms of neurodegeneration and to complete an ongoing Phase II study of KNS-760704 in
Proceeds from the offering will be used to advance Knopp’s discovery research targeting mitochondrial mechanisms of neurodegeneration and to complete an ongoing Phase II study of KNS-760704 in
The multi-center, double-blind, placebo controlled trial is a dose response study comparing 400mg and 600mg of Droxidopa to placebo in a total of 75 patients. Following a two-week
Revenue recognition for the announced new business contracts is expected to begin in the fourth quarter of 2008 on a proportional basis as services are performed on each
The new patent provides protection relating to rifaximin for treating irritable bowel syndrome (IBS) caused by small intestinal bacterial overgrowth. Salix has an exclusive license to this patent
The six month Fast 4Ward study met primary and secondary endpoints, and showed 400mg certolizumab pegol, given every four weeks as subcutaneous monotherapy, significantly reduced signs, symptoms and
Randy Moseley, who was serving as interim CEO until a permanent replacement was named, simultaneously resigned as interim CEO but will continue in his role as chairman of
The Phase II study was a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of MBX-8025, both alone and in combination with atorvastatin (marketed as Lipitor),
The agreement, which spans more than three dozen countries, excluding the US and Japan, will help to transform Lilly’s R&D organization as they seek to drive productivity, gain
Greg Andrews, vice president of marketing at Wellesse, said: “Liquid Vitamin D3 makes it easy for the entire family to reap the vitamin’s health benefits. Its great-tasting, fast-absorbing
Under the terms of the agreement TorreyPines will receive from QR Pharma an annual license fee, clinical and regulatory milestone payments, sublicensing fees and royalties on product sales.